J E Gschwend
Overview
Explore the profile of J E Gschwend including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Catto J, Tran B, Roupret M, Gschwend J, Loriot Y, Nishiyama H, et al.
Ann Oncol
. 2023 Oct;
35(1):98-106.
PMID: 37871701
Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations...
2.
Lewerich J, Schmid S, Gschwend J, Retz M
Urologie
. 2022 Nov;
62(3):279-287.
PMID: 36449033
Immune checkpoint inhibitors are standard of care in the treatment of metastatic and locally advanced urothelial cancer. Their use in perioperative treatment is currently under investigation as monotherapy as well...
3.
Ohlmann C, Kerkmann M, Holtmann L, Gschwend J, Retz M, de Wit M
Urologie
. 2022 Aug;
61(12):1351-1364.
PMID: 35925102
Background: The S3-guideline on bladder cancer recommends radical cystectomy and cisplatin-based perioperative chemotherapy (POC) for muscle-invasive bladder cancer (MIBC). Recommendation for metastatic urothelial cancer (mUC) is cisplatin-based or immuno-oncological (IO)...
4.
De Vincentis G, Gerritsen W, Gschwend J, Hacker M, Lewington V, OSullivan J, et al.
Ann Oncol
. 2019 Aug;
30(11):1728-1739.
PMID: 31418764
Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity....
5.
Linden A, Dinkel A, Schiele S, Meissner V, Gschwend J, Herkommer K
Urologe A
. 2019 Jun;
58(9):1039-1049.
PMID: 31172242
Background And Objective: The internet provides numerous sources of information about prostate cancer (PCa). The present study investigated internet use among long-term PCa survivors, trust in online PCa-related information, and...
6.
Maisch P, Gschwend J, Retz M
Urologe A
. 2018 Apr;
57(5):607-608.
PMID: 29623361
No abstract available.
7.
Storz E, Gschwend J, Retz M
Urologe A
. 2018 Mar;
57(5):532-542.
PMID: 29589051
The chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent side effects in cytostatic therapy and a profound challenge during the therapy of cancer patients. Therefore, standardized guideline-orientated...
8.
Maisch P, Gschwend J, Retz M
Urologe A
. 2018 Jan;
57(3):307-313.
PMID: 29322234
Background: Beside the classical anticancer treatment tumor patients try to find proactive alternative therapies to fight their disease. Lifestyle changes such as introducing a ketogenic diet is one of the...
9.
Gschwend J, Albers P, Bogemann M, Goebell P, Heidenreich A, Klier J, et al.
Urologe A
. 2017 Oct;
57(1):34-39.
PMID: 29071398
Background: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC)...
10.
Horn T, Rauscher I, Eiber M, Gschwend J, Maurer T
Urologe A
. 2017 Oct;
56(11):1417-1423.
PMID: 29022058
Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious...